Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNova Scotia Health Authority

About this trial

This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.

Eligibility criteria

Qualifiers

Age ≥18 years

Diagnosis of atrial fibrillation (documented on Holter, rhythm strip, or ECG)

New York Heart Association (NYHA) class II-III heart failure

Left ventricular ejection fraction (LVEF) >40%

Disqualifiers

Permanent atrial fibrillation diagnosis

Prior catheter ablation for atrial fibrillation

NYHA class IV heart failure

Rheumatic heart disease

Trial design

Treatments tested in this trial

  • Catheter Ablation for Atrial Fibrillation
  • Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)

Treatment groups

84 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Nova Scotia Health Authority

Lead sponsor

Heart and Stroke Foundation of Canada

Collaborator